المؤلفون: Ikeda S; Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, 969-3492, Japan. sp2x9ty9@gmail.com., Suzuki M; Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, 969-3492, Japan., Tsunoda S; Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, 969-3492, Japan., Ohta M; Department of Hematology, Fukushima Medical University Aizu Medical Center, Aizuwakamatsu, Fukushima, 969-3492, Japan.

المصدر: International journal of hematology [Int J Hematol] 2024 Sep; Vol. 120 (3), pp. 269-270. Date of Electronic Publication: 2024 Jul 15.

نوع المنشور: Letter

بيانات الدورية: Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnostic imaging , Magnetic Resonance Imaging*/methods , Bone Marrow*/pathology , Bone Marrow*/diagnostic imaging , Femur*/diagnostic imaging , Femur*/pathology, Humans ; Male ; Middle Aged ; Female ; Adult ; Aged

المؤلفون: Gong YX; Department of Physiology, School of Basic Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China., Yang ZJ; Department of Physiology, School of Basic Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China., Cao JM; Department of Physiology, School of Basic Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China., Liu HM; Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.

المصدر: Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2024 Aug; Vol. 32 (4), pp. 1078-1084.

نوع المنشور: English Abstract; Journal Article

بيانات الدورية: Publisher: Zhongguo shi yan xue za zhi she Country of Publication: China NLM ID: 101084424 Publication Model: Print Cited Medium: Print ISSN: 1009-2137 (Print) Linking ISSN: 10092137 NLM ISO Abbreviation: Zhongguo Shi Yan Xue Ye Xue Za Zhi Subsets: MEDLINE

مواضيع طبية MeSH: Imatinib Mesylate*/pharmacology , Nuclear Receptor Subfamily 4, Group A, Member 1*/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Apoptosis*/drug effects , Cell Proliferation*/drug effects , Proto-Oncogene Proteins c-pim-1*/metabolism, Humans ; K562 Cells ; Dynamins ; Signal Transduction ; Reactive Oxygen Species/metabolism ; Cell Movement

المؤلفون: Okamoto N; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan., Yagi K; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan., Imawaka S; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan., Takaoka M; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan., Aizawa F; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan., Niimura T; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan., Goda M; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan., Miyata K; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan., Kawada K; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan., Izawa-Ishizawa Y; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Department of General Medicine, Taoka Hospital, Tokushima, Japan., Sakaguchi S; Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.; Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan., Ishizawa K; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.; Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.

المصدر: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Aug; Vol. 12 (4), pp. e1214.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE

مواضيع طبية MeSH: Imatinib Mesylate*/pharmacology , Fusion Proteins, bcr-abl*/antagonists & inhibitors , Fusion Proteins, bcr-abl*/genetics , Drug Synergism* , Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics, Humans ; K562 Cells ; Protein Kinase Inhibitors/pharmacology ; Cell Survival/drug effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Agents/pharmacology ; Niacinamide/analogs & derivatives ; Pyrazoles

المؤلفون: Nemethova V; Selecta Biotech SE, Bratislava, Slovakia.; Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia., Babiakova P; Selecta Biotech SE, Bratislava, Slovakia., Teglasova B; Selecta Biotech SE, Bratislava, Slovakia., Uhelska L; Selecta Biotech SE, Bratislava, Slovakia., Babelova A; Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava, Slovakia., Selc M; Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava, Slovakia., Jakic K; Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Mitrovsky O; Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.; Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic., Myslivcova D; Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Zackova M; Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.; Department of Condensed Matter Physics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic., Poturnayova A; Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovakia., Batorova A; Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.; Department of Hematology and Transfusiology, Faculty of Medicine, Medical School Comenius University, Slovak Medical University, University Hospital, Bratislava, Slovakia., Drgona L; Department of Oncohematology, Comenius University and National Cancer Institute, Bratislava, Slovakia., Razga F; Selecta Biotech SE, Bratislava, Slovakia.; Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

المصدر: American journal of physiology. Cell physiology [Am J Physiol Cell Physiol] 2024 Jul 01; Vol. 327 (1), pp. C184-C192. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Physiological Society Country of Publication: United States NLM ID: 100901225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1563 (Electronic) Linking ISSN: 03636143 NLM ISO Abbreviation: Am J Physiol Cell Physiol Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology , Drug Resistance, Neoplasm*/drug effects , Protein Kinase Inhibitors*/pharmacology , Fusion Proteins, bcr-abl*/genetics , Fusion Proteins, bcr-abl*/antagonists & inhibitors , Fusion Proteins, bcr-abl*/metabolism , Oligonucleotides*/pharmacology , Apoptosis*/drug effects , Imatinib Mesylate*/pharmacology , Imatinib Mesylate*/therapeutic use, Humans ; Cell Line, Tumor ; Dasatinib/pharmacology ; Antineoplastic Agents/pharmacology ; Cell Survival/drug effects ; RNA, Messenger/genetics ; RNA, Messenger/metabolism

المؤلفون: Krumbholz M; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Loschgestrasse 15, 91054, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Dolnik A; Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Berlin, Germany., Sträng E; Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Berlin, Germany., Ghete T; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Loschgestrasse 15, 91054, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Skambraks S; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Hutter S; MLL Munich Leukemia Laboratory, Munich, Germany., Simonis A; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Loschgestrasse 15, 91054, Erlangen, Germany., Stegelmann F; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Suttorp M; Medical Faculty, Pediatric Hematology and Oncology, Technical University, Dresden, Germany., Horn AHC; Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.; Erlangen National High Performance Computing Center (NHR@FAU), Friedrich-Alexander- Universität Erlangen-Nürnberg, 91058, Erlangen, Germany., Sticht H; Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Bullinger L; Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Berlin, Germany.; Corporate member of Freie Universität Berlin and Humboldt, partner site Berlin, Universitätsmedizin Berlin, Universität zu Berlin, German Cancer Consortium (DKTK), Berlin, Germany., Metzler M; Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Loschgestrasse 15, 91054, Erlangen, Germany. Markus.Metzler@uk-erlangen.de.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. Markus.Metzler@uk-erlangen.de.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany. Markus.Metzler@uk-erlangen.de.

المصدر: Molecular cancer [Mol Cancer] 2024 Sep 26; Vol. 23 (1), pp. 206. Date of Electronic Publication: 2024 Sep 26.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology , Germ-Line Mutation* , Genetic Predisposition to Disease*, Humans ; Child ; Adolescent ; Male ; Female ; Child, Preschool ; Fusion Proteins, bcr-abl/genetics ; Adult ; Exome Sequencing ; Infant

المؤلفون: Zhao J; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China., Wang G; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China.; Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325036, China., Yan G; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China., Zheng M; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China., Li H; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China., Bai Y; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China., Zheng X; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China. jszhengxq@163.com.; School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, The Key Laboratory of Laboratory Medicine, Ministry of Education of China, Wenzhou, Zhejiang, 325035, China. jszhengxq@163.com., Chen Z; Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 1111 Wenzhou Avenue, Longwan District, Wenzhou, Zhejiang, 325024, China. steve0577@126.com.; The Key Laboratory of Pediatric Hematology and Oncology Diseases of Wenzhou, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. steve0577@126.com.

المصدر: BMC cancer [BMC Cancer] 2024 Sep 20; Vol. 24 (1), pp. 1172. Date of Electronic Publication: 2024 Sep 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/genetics , Disease Progression* , RNA, Circular*/blood , RNA, Circular*/genetics, Humans ; Male ; Female ; Prognosis ; Middle Aged ; Adult ; Aged ; Case-Control Studies

المؤلفون: Abruzzese E; From the Department of Hematology, S. Eugenio Hospital, Tor Vergata University, Azienda Sanitaria Locale Roma 2, Rome.

المصدر: The New England journal of medicine [N Engl J Med] 2024 Sep 12; Vol. 391 (10), pp. 955-957.

نوع المنشور: Editorial; Historical Article

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/history , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/history , Tyrosine Kinase Inhibitors*/administration & dosage , Tyrosine Kinase Inhibitors*/adverse effects , Tyrosine Kinase Inhibitors*/history, Humans ; Fusion Proteins, bcr-abl/antagonists & inhibitors ; Fusion Proteins, bcr-abl/genetics ; History, 20th Century ; History, 21st Century ; Clinical Trials, Phase III as Topic ; Imatinib Mesylate/administration & dosage ; Imatinib Mesylate/adverse effects ; Niacinamide/administration & dosage ; Niacinamide/adverse effects ; Niacinamide/analogs & derivatives ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Randomized Controlled Trials as Topic ; Treatment Outcome

المؤلفون: Eide CA; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Brewer D; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Xie T; Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Schultz AR; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Savage SL; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Muratcioglu S; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA., Merz N; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Press RD; Department of Pathology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., O'Hare T; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA., Jacob T; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA., Vu TQ; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA; Center for Spatial Systems Bioscience, Oregon Health & Science University, Portland, OR, USA., Tognon CE; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Macey TA; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Kuriyan J; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Chemistry, Vanderbilt College of Arts and Science, Nashville, TN, USA., Kalodimos CG; Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Druker BJ; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. Electronic address: drukerb@ohsu.edu.

المصدر: Cancer cell [Cancer Cell] 2024 Sep 09; Vol. 42 (9), pp. 1486-1488. Date of Electronic Publication: 2024 Aug 29.

نوع المنشور: Journal Article; Case Reports; Letter

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: Pyridazines*/therapeutic use , Pyridazines*/pharmacology , Fusion Proteins, bcr-abl*/genetics , Fusion Proteins, bcr-abl*/antagonists & inhibitors , Imidazoles*/pharmacology , Imidazoles*/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Drug Resistance, Neoplasm*/genetics , Drug Resistance, Neoplasm*/drug effects , Mutation* , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/pharmacology, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Male ; Female ; Niacinamide/analogs & derivatives ; Pyrazoles

المؤلفون: Polverelli N; Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili, Brescia, Italy.; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Anghilieri M; Oncology Department, ASST Lecco, Lecco, Italy., Elena C; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Intermesoli T; Unit of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy., Pungolino E; Unit of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., D'Adda M; Hematology Unit, ASST Spedali Civili, Brescia, Italy., Iurlo A; Unit of Hematology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Maffioli M; Unit of Hematology, ASST Sette Laghi, Varese, Italy., Lunghi F; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy., Bertolli V; Hematology Unit, ASST Valle Olona, Busto Arsizio, Italy., Orofino N; Division of Hematology, ASST Ovest Milanese, Legnano-Milan, Italy., Sissa C; Unit of Hematology, ASST Mantova, Mantova, Italy., Fiamenghi C; Unit of Hematology, ASST Cremona, Cremona, Italy., Gardellini A; Unit of Hematology, ASST Valduce, Como, Italy., Ubezio M; Unit of Hematology, IRCCS Humanitas Research Hospital, Rozzano, Italy., Carraro MC; Unit of Hematology, ASST Fatebenefratelli Sacco, Milan, Italy., Corradini P; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Giglio F; Division Oncohematology, European Institute of Oncology IRCCS, Milan, Italy., Pasquini MC; Unit of Oncology, ASST Crema, Crema, Italy., Palazzolo R; Unit of Hematology, ASST Valtellina e Alto Lario, Sondrio, Italy., Calori R; Oncology Department, ASST Brianza, Vimercate, Italy., Ercolanoni M; Agenzia Regionale per l'innovazione e gli acquisti (ARIA) S.p.A., Milan, Italy., Gambacorti-Passerini C; Department of Hematology, University of Milano Bicocca and Fondazione IRCCS San Gerardo, Monza, Italy.

المصدر: Hematological oncology [Hematol Oncol] 2024 Sep; Vol. 42 (5), pp. e3311.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/epidemiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Protein Kinase Inhibitors*/therapeutic use, Humans ; Italy/epidemiology ; Prevalence ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Adolescent ; Young Adult ; Registries

المؤلفون: Belohlavkova P; 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic., Zackova D; Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Klamova H; Institute of Haematology and Blood Transfusion, Prague, Czech Republic., Faber E; Department of Haemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic., Karas M; Department of Haemato-oncology, University Hospital Plzen and Charles University, Plzen, Czech Republic., Stejskal L; Department of Haemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic., Cmunt E; 1st Department of Internal Medicine-Haematology, General University Hospital and Charles University, Prague, Czech Republic., Cerna O; Department of Internal Medicine-Haematology, University Hospital Kralovske Vinohrady and Charles University, Prague, Czech Republic., Jeziskova I; Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Machova Polakova K; Institute of Haematology and Blood Transfusion, Prague, Czech Republic., Zak P; 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic., Jurkova T; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic., Chrapava M; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic., Mayer J; Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.

المصدر: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (17), pp. e70158.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Imatinib Mesylate*/therapeutic use , Imatinib Mesylate*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/mortality, Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Adult ; Aged ; Treatment Outcome ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Propensity Score ; Progression-Free Survival ; Young Adult